Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2016-10-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive quarterly financial report (Delårsrapport) for Orexo AB for the period January-September 2016. It contains detailed financial statements, management commentary, key performance indicators, and notes, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it provides substantive financial data and analysis. Q3 2016
2016-10-20 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the third quarter and the nine-month period ending September 2016. It contains detailed financial statements, management commentary, key figures, and notes, which are characteristic of an interim or quarterly report. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis itself. 9M 2016
2016-10-20 English
Delårsrapport Januari-September 2016
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive quarterly financial report (Delårsrapport) for Orexo AB for the period January-September 2016. It contains detailed financial statements, management commentary, key performance indicators, and notes, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it provides substantive financial data and analysis. Q3 2016
2016-10-20 Swedish
Interim Report January-September 2016
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the third quarter and the nine-month period ending September 2016. It contains detailed financial statements, management commentary, key figures, and notes, which are characteristic of an interim or quarterly report. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis itself. 9M 2016
2016-10-20 English
FDA godkänner unikt låg dos av Zubsolv®
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a significant event: the FDA approval of a new, uniquely low dose of Zubsolv®. It includes quotes from the CEO, details about the product, and contact information. This format is characteristic of an initial announcement of financial or material corporate news. Since it is an initial announcement of a major regulatory/product milestone, it fits best under 'Earnings Release' (ER) if it were financial results, but since it is a regulatory/product approval announcement that is not a full report, it is most appropriately classified as a general regulatory announcement or a specific type of corporate news release. Given the options, and recognizing this is a major corporate update/announcement rather than a full financial report (10-K, IR) or a transcript (CT), it aligns closely with the function of an Earnings Release (ER) which serves as the primary, immediate public disclosure of key performance/event information. However, since the core event is a regulatory approval (FDA), and it is a general press release format, 'Regulatory Filings' (RNS) is often used for non-standard, material announcements. Given the context of financial reporting databases, major product/regulatory milestones are often grouped with ERs or RNS. Since it is a direct announcement of a significant event (FDA approval) and not a report itself, and it is not explicitly about dividends, capital, or management changes, RNS (Regulatory Filings/General Announcement) is the most suitable fallback for a press release announcing a regulatory milestone not covered by other specific codes.
2016-10-06 Swedish
FDA Approves Unique Low Dosage of Zubsolv®
Regulatory Filings Classification · 1% confidence The document is titled "Press release" and announces a significant business event: the FDA approval of a new dosage of Zubsolv®. It includes key financial/operational highlights, quotes from the CEO, and contact information. This structure is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is announcing a specific regulatory/product milestone rather than summarizing overall quarterly financial performance (which would lean towards ER or IR), and it is not a formal regulatory filing like a 10-K or a general regulatory notice (RNS), it best fits the category for initial financial/product result announcements. Given the context of a major product approval and the format being a press release, 'Earnings Release' (ER) is the closest fit among the provided options for a significant, time-sensitive corporate announcement, although 'Regulatory Filings' (RNS) is also plausible if this were a mandatory disclosure. However, the content focuses on a product achievement, making ER the stronger classification for a major operational update presented as a press release.
2016-10-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.